News Sentiment

LGND sentiment intelligence

Ligand Pharmaceuticals Incorporated news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 274.88 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.6% over one week, +19.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $278.5, Implies 1% Upside

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.6% Price confirming higher
Trend fit Trend active 19.9% over four weeks
Fair value 124.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 48
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 21
Market source 7
simplywall.st 6
MarketBeat 5
TradingView 4
MT Newswires 4
GlobeNewswire 2
Trefis 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 16
Deals and strategy 10
Analyst action 4
Guidance 2
Capital return 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 72
Stock Titan Direct company coverage

JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo

JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 noti

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting fi

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 18:09
Source
Stock Titan
Stock Titan Direct company coverage

Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants

Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 07:40
Source
Stock Titan
Stock Titan Direct company coverage

LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition

Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earl

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 05:40
Source
Stock Titan
Market source Direct company coverage

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit

Tone
Positive 61/100
Event
Balance sheet
Published
07 Jun 2026 08:48
Source
Market source